menu
    • menu
    [{"orgOrder":0,"company":"ReproNovo","sponsor":"Jeito Capital","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2025","type":"Series A Financing","leadProduct":"Leflutrozole","moa":"Aromatase","graph1":"Endocrinology","graph2":"Phase II","graph3":"ReproNovo","amount2":0.070000000000000007,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0.070000000000000007,"dosageForm":"Oral","sponsorNew":"ReproNovo \/ Jeito Capital","highestDevelopmentStatusID":"8","companyTruncated":"ReproNovo \/ Jeito Capital"}]

    Find Endocrinology Clinical Drug Pipeline Developments & Deals by ReproNovo

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            ReproNovo

                            Switzerland arrow
                            Europ. Pharma Outsourcing
                            Not Confirmed

                            ReproNovo

                            Switzerland arrow
                            Europ. Pharma Outsourcing
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Leflutrozole

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase II

                            Sponsor : Jeito Capital

                            Deal Size : $65.0 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            ReproNovo Secures $65M Series A to Fund Phase 2 Trials in Reproductive Medicine

                            Details : The financing aims to advance the development of the company’s lead candidate, RPN-001 (leflutrozole), focusing on an orally administered therapy for infertility in men with low serum testosterone.

                            Product Name : RPN-001

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            May 21, 2025

                            Lead Product(s) : Leflutrozole

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase II

                            Sponsor : Jeito Capital

                            Deal Size : $65.0 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth